Undisclosed cancer-relevant transcription factor

The "Undisclosed cancer-relevant transcription factor" is a proprietary therapeutic target currently under investigation in the oncology pipeline of Relay Therapeutics. Transcription factors are a class of proteins that regulate gene expression by binding to specific DNA sequences, and their dysregulation is a hallmark of many cancers, driving processes such as uncontrolled cell growth, evasion of apoptosis, and metastasis. Historically, transcription factors have been categorized as "undruggable" due to their lack of well-defined small-molecule binding pockets and their reliance on protein-protein or protein-DNA interactions. Relay Therapeutics utilizes its Dynamo platform, which integrates experimental structural biology with computational motion-based simulations, to identify transient binding sites on such challenging targets. While the specific identity of this transcription factor remains confidential, it represents a high-value target for precision medicine, aiming to selectively inhibit oncogenic transcriptional programs while minimizing impact on normal cellular functions. The program highlights the industry's shift toward targeting previously inaccessible proteins through advanced computational and structural insights.

Other names

Undisclosed transcription factorRelay Therapeutics undisclosed targetUndisclosed oncology transcription factor

Inhibition of transcription factor activity or DNA binding